AbbVie Inc (ABBV)vsSagimet Biosciences Inc. Series A Common Stock (SGMT)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
SGMT
Sagimet Biosciences Inc. Series A Common Stock
$7.71
+0.92%
HEALTHCARE · Cap: $476.11M
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
SGMT
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.7%
Fair Value
$168.33
Current Price
$201.55
$33.22 premium
Intrinsic value data unavailable for SGMT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : SGMT
The strongest argument for SGMT centers on Debt/Equity, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : SGMT
The primary concerns for SGMT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
SGMT carries more volatility with a beta of 3.64 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 21/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Sagimet Biosciences Inc. Series A Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing transformative therapies for metabolic diseases, primarily targeting non-alcoholic steatohepatitis (NASH). The firm is progressing its lead therapeutic candidate through various clinical trial phases, utilizing unique mechanisms designed to enhance patient outcomes significantly. With a highly experienced leadership team and a robust intellectual property portfolio, Sagimet is strategically positioned to capitalize on the increasing market demand for effective metabolic disease treatments, making it an attractive investment opportunity for institutional investors seeking exposure in the dynamic biotech sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?